Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
MICROABSTRACT: Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 months (95% confidence interval, 17.5 to 30.8) confirming clinical benefit of durvalumab consolidation post-chemoradiotherapy in the real-world setting. INTRODUCTION: The Phase 3 PACIFIC trial established post-chemoradiotherapy (CRT) durvalumab consolidation as standard treatment for patients with unresectable, stage III non-small cell lung cancer (NSCLC). We present the results from the Australian subset of the multicentric PACIFIC-R study (NCT03798535) assessing the effectiveness of durvalumab in the real-world setting. PATIENTS AND METHODS: Patients with unresectable, stage III NSCLC without progression following CRT, receiving at least 1 dose of durvalumab (10 mg/kg intravenously, every 2 weeks) through an early access program (EAP) between September 2017 and December 2019, were enrolled. Primary endpoints, progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method. RESULTS: AS OF FEBRUARY 7, 2022, 165 PATIENTS (MEDIAN AGE: 67.0 years) with a median follow-up of 34.7 months were enrolled. Most received last radiation ≥42 days before durvalumab initiation (126, 79.2%) at a dose of 54 to 60 Gy (141, 88.7%). Median PFS was 22.4 months (95% confidence interval [CI], 17.5 to 30.8). The 3-year PFS and OS rates were 38.9% (95% CI, 31.0 to 46.7) and 59.1% (95% CI, 51.2 to 66.2). Pneumonitis was the most frequent adverse events of special interest (27, 16.4%); which led to treatment discontinuation in 19 (11.5%) patients. CONCLUSION: The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R
- Date Crossref
- 01/01/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Cabrini Hospital pays non établi dans la noticeÉtablissement de santé
-
Monash University pays non établi dans la noticeUniversité ou école supérieure
-
Chris O’Brien Lifehouse pays non établi dans la noticeOrganisation à but non lucratif
-
The University of Sydney Chris O'Brien Lifehouse pays non établi dans la noticeUniversité ou école supérieure
-
Royal North Shore Hospital pays non établi dans la noticeÉtablissement de santé
-
Liverpool Hospital pays non établi dans la noticeÉtablissement de santé
-
AstraZeneca (Australia) pays non établi dans la noticeEntreprise
-
Peter MacCallum Cancer Centre pays non établi dans la noticeÉtablissement de santé
Cabrini Hospital, Monash University et Chris O’Brien Lifehouse, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.